Clinical bottom line
Janus kinase (JAK) inhibitors have emerged as effective oral and topical therapies for moderate-to-severe atopic dermatitis (AD), offering rapid symptom relief by targeting key intracellular signaling pathways involved in inflammation. Current evidence supports their use in patients inadequately controlled by conventional treatments, with favorable efficacy demonstrated in clinical trials. However, safety concerns including infection risk and laboratory abnormalities necessitate careful patient selection and monitoring. JAK inhibitors represent a valuable addition to the therapeutic armamentarium for severe AD, complementing biologics and topical agents (Xie et al., 2025; Alraddadi et al., 2026).
What the evidence shows
Xie et al. (2025) provide an updated overview of AD pathophysiology and emerging therapies, highlighting that JAK inhibitors block multiple cytokine pathways central to type 2 inflammation, including IL-4, IL-13, and IL-31 signaling. This broad mechanism underpins their rapid and robust clinical efficacy.
Alraddadi et al. (2026) review the mechanisms and clinical trial data of JAK inhibitors such as upadacitinib, baricitinib, and abrocitinib, reporting significant improvements in Eczema Area and Severity Index (EASI) scores and pruritus reduction compared to placebo. They emphasize that oral JAK inhibitors achieve faster onset of action than biologics like dupilumab.
Lax et al. (2024) conducted a network meta-analysis comparing topical anti-inflammatory treatments, finding that topical JAK inhibitors demonstrate superior efficacy to corticosteroids and calcineurin inhibitors with an acceptable safety profile.
Nitulescu et al. (2025) discuss small molecule therapeutics targeting intracellular pathways, noting that JAK inhibitors’ oral bioavailability and ability to modulate multiple cytokines simultaneously provide advantages over single-target biologics.
Xin et al. (2025) present case studies illustrating successful use of JAK inhibitors in refractory AD, supporting their role in personalized treatment strategies.
Caveats and uncertainty
Long-term safety data for JAK inhibitors in AD remain limited, with concerns about serious infections, thrombosis, and laboratory abnormalities.
Comparative effectiveness versus established biologics requires further head-to-head trials.
Optimal duration of therapy and strategies for tapering or discontinuation are not well defined.
Potential risks in special populations such as children, pregnant women, and immunocompromised patients require further study.
Cost and access may limit widespread adoption.
How this may change practice
JAK inhibitors offer clinicians an effective oral and topical option for patients with severe AD who have failed or are intolerant to conventional therapies.
Early initiation may provide rapid symptom control, improving quality of life and reducing corticosteroid exposure.
Routine monitoring protocols should be implemented to detect adverse events promptly.
Integration of JAK inhibitors into treatment algorithms alongside biologics will require individualized assessment of efficacy, safety, and patient preference.
Education on risk mitigation and adherence is essential to optimize outcomes.